Synmosa Biopharma (4114) - Total Liabilities

Latest as of December 2025: NT$3.89 Billion TWD ≈ $122.43 Million USD

Based on the latest financial reports, Synmosa Biopharma (4114) has total liabilities worth NT$3.89 Billion TWD (≈ $122.43 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Synmosa Biopharma long-term investment intensity to see how much of total assets are deployed in long-term investments.

Synmosa Biopharma - Total Liabilities Trend (2015–2025)

This chart illustrates how Synmosa Biopharma's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Synmosa Biopharma (4114) total assets.

Synmosa Biopharma Competitors by Total Liabilities

The table below lists competitors of Synmosa Biopharma ranked by their total liabilities.

Company	Country	Total Liabilities
Visco Vision Inc. TW:6782	Taiwan	NT$1.84 Billion
Guangdong Zhengye Technology Co Ltd SHE:300410	China	CN¥1.43 Billion
Sligro Food Group NV AS:SLIGR	Netherlands	€1.07 Billion
ChoiceOne Financial Services Inc NASDAQ:COFS	USA	$3.92 Billion
YeaShin International Development Co Ltd TWO:5213	Taiwan	NT$53.02 Billion
Logan Energy Corp V:LGN	Canada	CA$73.27 Million
Optotech Corp TW:2340	Taiwan	NT$7.48 Billion
Lake Materials Co. Ltd. KQ:281740	Korea	₩254.24 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down Synmosa Biopharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Synmosa Biopharma (4114) net asset quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.95	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.44	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.28	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Synmosa Biopharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Synmosa Biopharma (2015–2025)

The table below shows the annual total liabilities of Synmosa Biopharma from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	NT$3.89 Billion ≈ $122.43 Million	-0.49%
2024-12-31	NT$3.91 Billion ≈ $123.04 Million	+7.65%
2023-12-31	NT$3.63 Billion ≈ $114.29 Million	-20.34%
2022-12-31	NT$4.55 Billion ≈ $143.47 Million	+7.87%
2021-12-31	NT$4.22 Billion ≈ $133.00 Million	-4.55%
2020-12-31	NT$4.42 Billion ≈ $139.34 Million	+12.91%
2019-12-31	NT$3.92 Billion ≈ $123.41 Million	+28.03%
2018-12-31	NT$3.06 Billion ≈ $96.39 Million	-13.54%
2017-12-31	NT$3.54 Billion ≈ $111.48 Million	+45.22%
2016-12-31	NT$2.44 Billion ≈ $76.77 Million	+54.36%
2015-12-31	NT$1.58 Billion ≈ $49.73 Million	--

About Synmosa Biopharma

TWO:4114 Taiwan Drug Manufacturers - Specialty & Generic

Market Cap

$470.87 Million

NT$14.95 Billion TWD

Market Cap Rank

#12751 Global

#472 in Taiwan

Share Price

NT$29.60

Change (1 day)

+0.00%

52-Week Range

NT$28.90 - NT$34.65

All Time High

NT$6197.22